Genmab — Maj 2019
-
God morgen
-
God morgen.
-
-
@NoHope, 2 sjæle en tanke
-
Poseida Therapeutics Reseives US FDA Orphan Drug designation for P-BCMA 101 for the treatment of MM https://m.firstwordpharma.com/poseida-therapeutics-receives-us-fda-orphan-drug-designation-p-bcma-101-treatment-multiple-myeloma
-
-
-
Synes ikke der er meget RTOR over den MAIA ansøgning. Jeg ved ikke om jeg forstår den her tegning https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review-pilot-program men kan det passe at Janssen completed sBLA submission den 12. marts? https://johnsonandjohnson.gcs-web.com/static-files/5cec96a8-449f-4608-8890-a83c0b00d0b9 Herfra går der ifølge FDA ca. 4 uger? nu er der så gået 8 uger.
-
Winkel fra CC om RTOR og Maia: It's up to the gods at the FDA right now, but I think the process is going well, and there is no reason to be concerned at all. It's an experimental program. It's a pilot program. So the time lines are not fixed, but we expect it very, very shortly.
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company AnnouncementCopenhagen, Denmark; May 14, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,737 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
3,000 shares at DKK 40.41,
5,000 s
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind